Chinese Journal of Organic Chemistry Previous Articles     Next Articles



张丹青a,b, 柳旭a,b, 庞晓静a,b, 刘宏民a,b,c, 张秋荣a,b,c   

  1. a 郑州大学药学院 郑州 450001;
    b 新药创制与药物安全性评价河南省协同创新中心 郑州 450001;
    c 教育部药物制备关键技术重点实验室 郑州 450001
  • 出版日期:2030-01-01 发布日期:2020-09-16
  • 通讯作者: 刘宏民, 张秋荣;
  • 基金资助:

Design, Synthesis and Anticancer Activity Studies of Novel Indole-Pyrimidine Biaryl Derivatives

Dan-Qing Zhanga,b, Xu Liua,b, Xiao-Jing Panga,b, Hong-Min Liua,b,c, Qiu-Rong Zhanga,b,c   

  1. a School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001;
    b Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Zhengzhou 450001) (c Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Zhengzhou 450001
  • Online:2030-01-01 Published:2020-09-16
  • Supported by:
    Project supported by Key Research Program of Proteins (No. 2018YFE0195100) and Openning fund from State Key Laboratory of Esophageal Cancer Prevention & Treatment (No. K2020000X)

A series of novel indole-pyrimidine biaryl derivatives were designed, synthesized and evaluated for inhibitory activity against LSD1 and antiproliferative activity against five selected cancer cell lines (MGC-803, PC-3, EC-109, PC-12 and MCF-7). The priliminary structure-activity relationship (SAR) for this indole-pyrimidine biaryl scaffold is explored in this report with evaluation of 22 variants of the structural class. Among these analogues, compound 6i exhibited the potential inhibitory activity against LSD1 (IC50=1.03 µM), compounds 6c, 6f and 6k showed the potential inhibitory activity aginst PC-3 cells. Especially, compound 6k exhibited the best antitumor activity (IC50=2.75 µM), which was served as bioactive fragment and hit compound for developing more potent antitumor agents.

Key words: Indole, Pyrimidine, Biaryl, Antitumor